{
    "id": 979,
    "fullName": "KRAS G12C",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "KRAS G12C is a hotspot mutation that lies within a GTP-binding region of the Kras protein (UniProt.org). G12C results in decreased Kras GTPase activity and activation of downstream signaling in cell culture and mouse models (PMID: 26037647 PMID: 16051643, PMID: 23455880).",
            "references": [
                {
                    "id": 3052,
                    "pubMedId": 26037647,
                    "title": "Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26037647"
                },
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 436,
                    "pubMedId": 16051643,
                    "title": "Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16051643"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "G12C",
    "createDate": "07/14/2014",
    "updateDate": "10/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 157050,
        "transcript": "NM_033360",
        "gDna": "chr12:g.25245351C>A",
        "cDna": "c.34G>T",
        "protein": "p.G12C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2758,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0623 induced tumor regression in pancreatic cancer cell line xenograft models harboring KRAS G12C (PMID: 23934108).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 748,
                "therapyName": "GDC-0623",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 187,
                    "pubMedId": 23934108,
                    "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23934108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8789,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-847325 induced sustained tumor regression in pancreatic adenocarcinoma cell line xenograft models harboring KRAS G12C (PMID: 27496137).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6751,
                    "pubMedId": 27496137,
                    "title": "Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496137"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including Mekinist (trametinib), in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11323,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cell lines harboring KRAS G12C, and anti-tumor activity in cell line xenograft models (PMID: 28615361).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19319,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 inhibited Erk phosphorylation, cell proliferation, and induced apoptosis in lung cancer cell lines harboring KRAS G12C in culture, resulted in tumor growth inhibition and regression in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19018,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Tarceva (erlotinib) synergistically inhibited growth of pancreatic cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8874,
                "therapyName": "AMG 510 + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15041,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic ductal adenocarcinoma cells harboring KRAS G12C demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture when compared to the combined therapy of Selumetinib (AZD6244) and SHP099 (PMID: 30045908).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torisel (temsirolimus) and Linsitinib (OSI-906) combination treatment demonstrated enhanced growth inhibition compared to Torisel (temsirolimus) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8805,
                "therapyName": "Linsitinib + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18629,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torisel (temsirolimus), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment demonstrated enhanced growth inhibition compared to Torisel (temsirolimus) alone or in combination with either Linsitinib (OSI-906) or Mekinist (trametinib) in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8806,
                "therapyName": "Linsitinib + Temsirolimus + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3568,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CID1067700 inhibited growth and increased apoptosis of non-small cell lung cancer cells that harbor KRAS G12C in culture (PMID: 26247207, PMID: 19477428).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 3158,
                "therapyName": "CID1067700",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3837,
                    "pubMedId": 26247207,
                    "title": "A Pan-GTPase Inhibitor as a Molecular Probe.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26247207"
                },
                {
                    "id": 4103,
                    "pubMedId": 19477428,
                    "title": "A gene expression signature associated with \"K-Ras addiction\" reveals regulators of EMT and tumor cell survival.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19477428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19020,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Mekinist (trametinib) synergistically inhibited growth of pancreatic cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8876,
                "therapyName": "AMG 510 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10763,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/Ib trial, the subgroup of non-small cell lung cancer patients harboring KRAS G12C demonstrated a disease control rate (DCR) of 80% (8/10; 4 partial responses, 4 stable disease) following treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel), compared to a DCR of 60% (15/25) in the overall KRAS-mutant population (PMID: 27876675).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 1264,
                "therapyName": "Docetaxel + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8810,
                    "pubMedId": 27876675,
                    "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18687,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS1620, Linsitinib (OSI-906), and Afinitor (everolimus) triple combination treatment enhanced inhibition of AKT, S6, and ERK phosphorylation, resulted in durable growth inhibition and apoptosis compared to ARS1620 alone or in combination with either Linsitinib (OSI-906) or Afinitor (everolimus) in non-small cell lung cancer cell lines harboring KRAS G12C in culture, and lead to tumor regression in cell line xenograft models (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8792,
                "therapyName": "ARS1620 + Everolimus + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19017,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Gilotrif (afatinib) synergistically inhibited growth of pancreatic cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8873,
                "therapyName": "Afatinib + AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19011,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Gilotrif (afatinib) synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8873,
                "therapyName": "Afatinib + AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19023,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and PD-0325901 synergistically inhibited tumor growth in cell line xenograft models of lung cancer harboring KRAS G12C (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8880,
                "therapyName": "AMG 510 + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19000,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 inhibited Erk1/2 phosphorylation and viability of pancreatic cancer cells harboring KRAS G12C in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Afinitor (everolimus) and Linsitinib (OSI-906) inhibited PI3K/AKT and mTOR signaling, resulted in synergistic growth inhibition and apoptosis in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8785,
                "therapyName": "Everolimus + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4536,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 1386,
                "therapyName": "Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20601,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-2852 treatment inhibited phosphorylation of Erk and Akt and proliferation of lung cancer cells harboring G12C in culture (PMID: 31332011).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9408,
                "therapyName": "BI-2852",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17956,
                    "pubMedId": 31332011,
                    "title": "Drugging an undruggable pocket on KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31332011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19318,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 inhibited Erk phosphorylation, cell proliferation, and induced apoptosis in a pancreatic cancer cell line harboring KRAS G12C in culture, resulted in tumor regression in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15707,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in pancreatic cancer cells harboring KRAS G12C, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11466,
                    "pubMedId": 28939558,
                    "title": "Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28939558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19328,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and RMC-4550 combination treatment resulted in enhanced inhibition of KRAS pathway signaling in lung cancer cell lines harboring KRAS G12C in culture, and greater tumor growth inhibition in cell line xenograft models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8997,
                "therapyName": "MRTX849 + RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12135,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by Selumetinib (AZD6244) in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19321,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 inhibited viability of a cervical cancer cell line harboring KRAS G12C in culture, and induced tumor regression in cell line xenograft models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 4362,
                "name": "cervical cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18622,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Mekinist (trametinib) combination treatment demonstrated enhanced growth inhibition and induction of apoptosis compared to Afinitor (everolimus) alone in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 1271,
                "therapyName": "Everolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8996,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6848,
                    "pubMedId": 27422710,
                    "title": "Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422710"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19331,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Gilotrif (afatinib) combination treatment synergistically inhibited cell proliferation, and induced apoptosis in an esophageal cancer cell line harboring KRAS G12C in culture, and inhibited tumor growth in cell line xenograft models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8998,
                "therapyName": "Afatinib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7869,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS-853 treatment in culture resulted in decreased cell proliferation and apoptotic induction in non-small cell lung carcinoma cells harboring KRAS G12C (PMID: 26841430).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 3553,
                "therapyName": "ARS-853",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5919,
                    "pubMedId": 26841430,
                    "title": "Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26841430"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and BMS-754807 combination treatment demonstrated enhanced growth inhibition compared to Afinitor (everolimus) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8793,
                "therapyName": "BMS-754807 + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12321,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring KRAS G12C in culture that had, over time, acquired resistance to Selumetinib (AZD6244) showed decreased drug resistance when treatment was combined with Filgotinib (GLPG0634), demonstrating reduced expression of Osmr and phosphorylated-Stat3, and decreased cell viability (PMID: 28729401).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 6456,
                "therapyName": "GLPG0634 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10327,
                    "pubMedId": 28729401,
                    "title": "JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1447,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring KRAS G12C (PMID: 23934108).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 187,
                    "pubMedId": 23934108,
                    "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23934108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17270,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG 510 treatment resulted in partial response in 2 patient and stable disease in 2 patients with advanced non-small cell lung cancer harboring KRAS G12C (PMID: 31666701; NCT03600883).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18449,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG 510 demonstrated safety and preliminary efficacy, resulted in partial response in 54% (7/13) and stable disease in 46% (6/13) of patients with non-small cell lung cancer harboring KRAS G12C (IASLC 2019 World Conference on Lung Cancer, Sep 2019, Abstract OA02.02).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16184,
                    "pubMedId": null,
                    "title": "PHASE 1 STUDY OF SAFETY, TOLERABILITY, PK AND EFFICACY OF AMG 510, A NOVEL KRASG12C INHIBITOR, EVALUATED IN NSCLC",
                    "url": "https://wclc2019.iaslc.org/wp-content/uploads/2019/08/WCLC2019-Abstract-Book_web-friendly.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19896,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12136,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including PD-0325901, in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torisel (temsirolimus) and Mekinist (trametinib) combination treatment demonstrated enhanced growth inhibition compared to Torisel (temsirolimus) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8804,
                "therapyName": "Temsirolimus + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17307,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX1257 inhibited KRAS downstream signaling and proliferation in a panel of tumor cell lines harboring KRAS G12C, and resulted in tumor regression in multiple animal models (AACR Annual Meeting 2019, Abstract LB-271).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8452,
                "therapyName": "MRTX1257",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15358,
                    "pubMedId": null,
                    "title": "Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9179"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2490,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response (PR) in 8.8% (5/57) and stable disease (SD) in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer, including SD in 12 patients and PR in 3 patients with KRAS G12C (PMID: 23224737).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3164,
                    "pubMedId": 23224737,
                    "title": "A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23224737"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 802,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line harboring the KRAS G12C mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 26,
                    "pubMedId": 23455880,
                    "title": "KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23455880"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17371,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3214996 and LY3009120 synergistically inhibited phosphorylation of Erk, Rb, S6, and H3, resulted in enhanced cell death in non-small cell lung cancer cells harboring KRAS G12C in culture (AACR Annual Meeting 2019, Abstract LB-083).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8468,
                "therapyName": "LY3009120 + LY3214996",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15395,
                    "pubMedId": null,
                    "title": "Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9241"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8055, Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment demonstrated enhanced growth inhibition and induction of apoptosis compared to AZD8055 alone or in combination with either Linsitinib (OSI-906) or Mekinist (trametinib) in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8788,
                "therapyName": "AZD8055 + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of AZD8055 and Linsitinib (OSI-906) inhibited PI3K/AKT and mTOR signaling, resulted in synergistic growth inhibition and apoptosis in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8787,
                "therapyName": "AZD8055 + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19026,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of AMG 510 and anti-PD-1 antibody resulted in sustained complete response in mouse syngeneic models of lung cancer driven by KRAS G12C (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8882,
                "therapyName": "AMG 510 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19015,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and AMG 511 synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8879,
                "therapyName": "AMG 510 + AMG 511",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment inhibited PI3K/AKT and RAF/MEK/ERK signaling, resulted in enhanced growth inhibition and induction of apoptosis compared to Afinitor (everolimus) alone or in combination with either Linsitinib (OSI-906) or Mekinist (trametinib) in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8786,
                "therapyName": "Everolimus + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19013,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and RMC-4550 synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8875,
                "therapyName": "AMG 510 + RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torkinib (PP242) and Mekinist (trametinib) combination treatment demonstrated enhanced growth inhibition compared to Torkinib (PP242) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8799,
                "therapyName": "Torkinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19003,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 inhibited Erk1/2 phosphorylation and viability of bladder cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19021,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and AMG 511 synergistically inhibited growth of pancreatic cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8879,
                "therapyName": "AMG 510 + AMG 511",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19014,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Mekinist (trametinib) synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8876,
                "therapyName": "AMG 510 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS1620 and Linsitinib (OSI-906) combination treatment enhanced inhibition of AKT, S6, and ERK phosphorylation, resulted in greater growth inhibition and apoptosis compared to ARS1620 alone in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8790,
                "therapyName": "ARS1620 + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) combination treatment synergistically inhibited growth of a colon cancer cell line harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19333,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Vistusertib (AZD2014) combination treatment inhibited KRAS and mTOR signaling in an esophageal cancer cell line harboring KRAS G12C in culture, and induced tumor regression in cell line xenograft models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8999,
                "therapyName": "MRTX849 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19895,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Ibrance (palbociclib) combination treatment synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9001,
                "therapyName": "MRTX849 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15048,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Mekinist (trametinib) and SHP099 led to reduced cell viability in pancreatic ductal adenocarcinoma cells harboring KRAS G12C in culture (PMID: 30045908).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7401,
                "therapyName": "SHP099 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18638,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8055 and NVP-AEW541 combination treatment demonstrated enhanced growth inhibition compared to Afinitor (everolimus) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8795,
                "therapyName": "AZD8055 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3137,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human pancreatic cancer cell lines harboring KRAS G12C in culture (PMID: 21325073, PMID: 12068308).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                },
                {
                    "id": 637,
                    "pubMedId": 12068308,
                    "title": "Mutations of the BRAF gene in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12068308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15996,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 decreased RAS-GTP level, inhibited Erk phosphorylation and proliferation of lung cancer cell lines harboring KRAS G12C in culture, resulted in dose-dependent tumor growth inhibition in cell line xenograft models (PMID: 30104724).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and Linsitinib (OSI-906) combination treatment demonstrated enhanced growth inhibition compared to Sapanisertib (MLN0128) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8801,
                "therapyName": "Linsitinib + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment demonstrated enhanced growth inhibition compared to Sapanisertib (MLN0128) alone or in combination with either Linsitinib (OSI-906) or Mekinist (trametinib) in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8803,
                "therapyName": "Linsitinib + Sapanisertib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS1620 and Afinitor (everolimus) combination treatment enhanced inhibition of AKT, S6, and ERK phosphorylation, resulted in greater growth inhibition and apoptosis compared to ARS1620 alone in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8791,
                "therapyName": "ARS1620 + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16000,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 treatment resulted in decreased Erk phosphorylation and dose-dependent tumor growth inhibition in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring KRAS G12C (PMID: 30104724).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8055 and Mekinist (trametinib) combination treatment demonstrated enhanced growth inhibition and induction of apoptosis compared to AZD8055 alone in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8789,
                "therapyName": "AZD8055 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4619,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS-853 inhibited growth of several human tumor cell lines harboring KRAS G12C in 3-dimensional culture conditions (PMID: 26739882).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 3553,
                "therapyName": "ARS-853",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4628,
                    "pubMedId": 26739882,
                    "title": "Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26739882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19329,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and RMC-4550 combination treatment resulted in enhanced inhibition of KRAS pathway signaling in esophageal cancer cells harboring KRAS G12C in culture, and greater tumor growth inhibition in cell line xenograft models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8997,
                "therapyName": "MRTX849 + RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17398,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 inhibited KRAS G12C signaling in tumor cell lines in culture, resulted in tumor regression in cell line xenograft models (Proceedings of AACR Annual Meeting 2019, Vol 60, Abstract# 3090).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15418,
                    "pubMedId": null,
                    "title": "In vivo characterization of AMG 510 - a potent and selective KRAS G12C covalent small molecule inhibitor in preclinical KRAS G12C cancer models.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16034,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS1620 and Pictilisib (GDC-0941) demonstrated synergy in several non-small cell lung cancer (NSCLC) cell lines harboring KRAS G12C in culture, and treatment with the combination resulted in prolonged tumor stabilization or tumor regression in ARS1620-resistant KRAS G12C-mutant NSCLC cell line xenograft models, and patient-derived xenograft (PDX) models harboring KRAS G12C demonstrated increased sensitivity to the combination compared to either agent alone (PMID: 30327306).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7863,
                "therapyName": "ARS1620 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14151,
                    "pubMedId": 30327306,
                    "title": "KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30327306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11332,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4785 inhibited Kras expression and downstream signaling, resulted in tumor growth inhibition in patient-derived xenograft models of lung cancer harboring KRAS G12C (PMID: 28615361).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18632,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torkinib (PP242), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment demonstrated enhanced growth inhibition compared to Torkinib (PP242) alone or in combination with either Linsitinib (OSI-906) or Mekinist (trametinib) in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8800,
                "therapyName": "Linsitinib + Torkinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus), Pictilisib (GDC-0941), and Mekinist (trametinib) triple combination treatment demonstrated enhanced growth inhibition in non-small cell lung cancer cell lines harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8797,
                "therapyName": "Everolimus + Pictilisib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18639,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8055 and BMS-754807 combination treatment demonstrated enhanced growth inhibition compared to Afinitor (everolimus) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8794,
                "therapyName": "AZD8055 + BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17271,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG 510 treatment resulted in stable disease in 4 patients with advanced colorectal cancer harboring KRAS G12C (J Clin Oncol 37, 2019 (suppl; abstr 3003); NCT03600883).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15303,
                    "pubMedId": null,
                    "title": "Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.",
                    "url": "https://abstracts.asco.org/239/AbstView_239_268371.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19019,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and RMC-4550 synergistically inhibited growth of pancreatic cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8875,
                "therapyName": "AMG 510 + RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19001,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 inhibited Erk1/2 phosphorylation and viability of lung cancer cell lines harboring KRAS G12C in culture, resulted in tumor regression in cell line xenograft and patient-derived xenograft models (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19330,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Gilotrif (afatinib) combination treatment synergistically inhibited proliferation of lung cancer cells harboring KRAS G12C in culture, and inhibited tumor growth in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8998,
                "therapyName": "Afatinib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19022,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Capivasertib (AZD5363) synergistically inhibited growth of pancreatic cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8877,
                "therapyName": "AMG 510 + Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12138,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including Refametinib (BAY86-9766), in culture (PMID: 28957417).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10109,
                    "pubMedId": 28957417,
                    "title": "Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28957417"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16024,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited growth of rectal cancer cells harboring KRAS G12C in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1993,
                "name": "rectum cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15043,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Selumetinib (AZD6244) and SHP099 resulted in a synergistic effect, demonstrating reduced cell proliferation and decreased colony formation in pancreatic ductal adenocarcinoma cells harboring KRAS G12C (PMID: 30045908).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7400,
                "therapyName": "Selumetinib + SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8988,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6848,
                    "pubMedId": 27422710,
                    "title": "Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422710"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19898,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4538,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human lung cells harboring KRAS G12C in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 3532,
                "therapyName": "Trametinib + TW-37",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14384,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma patient-derived xenograft (PDX) model was sensitive to treatment with Gilotrif (afatinib), demonstrating inhibition of tumor growth (PMID: 29925635).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11625,
                    "pubMedId": 29925635,
                    "title": "Afatinib restrains K-RAS-driven lung tumorigenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29925635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19327,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, MRTX849 treatment resulted in a partial response of target lesions and a complete response of a nontarget lesion after 3 cycles of treatment in a patient with metastatic colon adenocarcinoma harboring KRAS G12C, and the patient remained on treatment through cycle 6 (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 234,
                "name": "colon adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19332,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Vistusertib (AZD2014) combination treatment inhibited KRAS and mTOR signaling in lung cancer cell lines harboring KRAS G12C, resulted in synergistic inhibition of cell growth in culture, and tumor regression in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8999,
                "therapyName": "MRTX849 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19016,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Capivasertib (AZD5363) synergistically inhibited growth of lung cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8877,
                "therapyName": "AMG 510 + Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torkinib (PP242) and Linsitinib (OSI-906) combination treatment demonstrated enhanced growth inhibition compared to Torkinib (PP242) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8798,
                "therapyName": "Linsitinib + Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19323,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 treatment inhibited viability of urinary bladder cancer cells harboring KRAS G12C in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19024,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of AMG 510 and Paraplatin (carboplatin) demonstrated enhanced tumor growth inhibition in cell line xenograft models of lung cancer harboring KRAS G12C (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8881,
                "therapyName": "AMG 510 + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19012,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 and Tarceva (erlotinib) synergistically inhibited growth of lung cancer cells harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8874,
                "therapyName": "AMG 510 + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10313,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring KRAS G12C in culture (PMID: 28179366).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 3505,
                "therapyName": "Cetuximab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8298,
                    "pubMedId": 28179366,
                    "title": "Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28179366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19320,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 inhibited viability of a colorectal cancer cell line harboring KRAS G12C in culture, and inhibited tumor growth and induced regression in a cell line xenograft model (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7356,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and SCH772984 combination treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 4476,
                "therapyName": "SCH772984 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16023,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited growth of esophageal cancer cells harboring KRAS G12C in 3D culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and NVP-AEW541 combination treatment demonstrated enhanced growth inhibition compared to Afinitor (everolimus) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8796,
                "therapyName": "Everolimus + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1446,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12C (PMID: 23934108).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 187,
                    "pubMedId": 23934108,
                    "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23934108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15997,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 decreased RAS-GTP level, inhibited Erk phosphorylation and proliferation of pancreatic cancer cells harboring KRAS G12C in culture, resulted in dose-dependent tumor growth inhibition in cell line xenograft models (PMID: 30104724).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and Linsitinib (OSI-906) combination treatment demonstrated enhanced growth inhibition compared to Sapanisertib (MLN0128) alone in non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8802,
                "therapyName": "Sapanisertib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2618,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, NSCLC patients harboring KRAS G12C or G12V mutations demonstrated a trend towards better overall survival, progression free survival, and objective response rate compared to NSCLC patients with other KRAS mutations when treated with the combination therapy, Selumetinib (AZD6244) and Taxotere (docetaxel) (PMID: 26125448).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 1117,
                "therapyName": "Docetaxel + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3343,
                    "pubMedId": 26125448,
                    "title": "Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26125448"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2770,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SML-10-70-1 inhibited proliferation and Erk/Akt signaling in non-small cell lung cancer cells expressing KRAS G12C in culture (PMID: 24259466).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 2227,
                "therapyName": "SML-10-70-1",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2046,
                    "pubMedId": 24259466,
                    "title": "Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24259466"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19322,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 treatment partially inhibited Erk phosphorylation, resulted in a minor inhibition of cell growth in culture and a tumor growth inhibition that was not statistically significant in cell line xenograft models of esophageal cancer harboring KRAS G12C (PMID: 31658955).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19002,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 510 inhibited Erk1/2 phosphorylation and viability of colon cancer cell lines harboring KRAS G12C in culture (PMID: 31666701).",
            "molecularProfile": {
                "id": 1042,
                "profileName": "KRAS G12C"
            },
            "therapy": {
                "id": 8435,
                "therapyName": "AMG 510",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16672,
                    "pubMedId": 31666701,
                    "title": "The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31666701"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4517,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YAP1 knockdown enhanced sensitivity of human non-small cell lung cancer cell lines harboring KRAS G12C to Mekinist (trametinib) inhibition in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 18272,
                "profileName": "KRAS G12C YAP1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4624,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with LY2874455 resulted in decreased ERK pathway activation and reduced viability of non-small cell lung cancer (NSCLC) cells harboring FGFR4 P712T along with KRAS G12C in culture, and did not effect viability of NSCLC cells lacking FGFR4 activating mutations (PMID: 23836671).",
            "molecularProfile": {
                "id": 18651,
                "profileName": "FGFR4 P712T KRAS G12C"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1133,
                    "pubMedId": 23836671,
                    "title": "Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836671"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1389,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) reduced MEK pathway activation and promoted apoptosis of lung cancer cells harboring KRAS G12C and FGFR4 P712T mutations in culture (PMID: 23836671).",
            "molecularProfile": {
                "id": 18651,
                "profileName": "FGFR4 P712T KRAS G12C"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1133,
                    "pubMedId": 23836671,
                    "title": "Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836671"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7357,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Mapk1 expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25299,
                "profileName": "KRAS G12C MAPK1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7358,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Raf1 expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25300,
                "profileName": "KRAS G12C RAF1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7359,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Braf expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25302,
                "profileName": "BRAF dec exp KRAS G12C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7893,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 26088,
                "profileName": "BRAF wild-type KRAS G12C"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8521,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26341,
                "profileName": "EZH2 pos KRAS G12C"
            },
            "therapy": {
                "id": 4747,
                "therapyName": "DZNeP + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8503,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26341,
                "profileName": "EZH2 pos KRAS G12C"
            },
            "therapy": {
                "id": 4748,
                "therapyName": "Selumetinib + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26341,
                "profileName": "EZH2 pos KRAS G12C"
            },
            "therapy": {
                "id": 4750,
                "therapyName": "GSK343 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8517,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26341,
                "profileName": "EZH2 pos KRAS G12C"
            },
            "therapy": {
                "id": 4746,
                "therapyName": "DZNeP + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8510,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756).",
            "molecularProfile": {
                "id": 26341,
                "profileName": "EZH2 pos KRAS G12C"
            },
            "therapy": {
                "id": 4747,
                "therapyName": "DZNeP + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8512,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26341,
                "profileName": "EZH2 pos KRAS G12C"
            },
            "therapy": {
                "id": 4751,
                "therapyName": "GSK343 + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8513,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",
            "molecularProfile": {
                "id": 26341,
                "profileName": "EZH2 pos KRAS G12C"
            },
            "therapy": {
                "id": 4749,
                "therapyName": "MK2206 + Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8498,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C, in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",
            "molecularProfile": {
                "id": 26341,
                "profileName": "EZH2 pos KRAS G12C"
            },
            "therapy": {
                "id": 4746,
                "therapyName": "DZNeP + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6667,
                    "pubMedId": 26676756,
                    "title": "Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676756"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8577,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",
            "molecularProfile": {
                "id": 26366,
                "profileName": "KRAS G12C PIK3CA H1047R TP53 R248W"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11908,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Mekinist (trametinib) in a lung cancer cell line harboring KRAS G12C in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28338,
                "profileName": "KEAP1 loss KRAS G12C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of NFE2L2 (NRF2) G31R resulted in decreased sensitivity to Mekinist (trametinib) in a lung cancer cell line harboring KRAS G12C in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28346,
                "profileName": "KRAS G12C NFE2L2 G31R NFE2L2 over exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14586,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK and KRAS G12C demonstrated a minimal response when treated with Xalkori (crizotinib), and eventually progressed (PMID: 29636358).",
            "molecularProfile": {
                "id": 30253,
                "profileName": "EML4 - ALK KRAS G12C"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15053,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic ductal adenocarcinoma cells harboring KRAS G12C and expressing PTPN11 P491Q were resistant to the combination therapy, Selumetinib (AZD6244) and SHP099, in culture (PMID: 30045908).",
            "molecularProfile": {
                "id": 30712,
                "profileName": "KRAS G12C PTPN11 P491Q"
            },
            "therapy": {
                "id": 7400,
                "therapyName": "Selumetinib + SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18126,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHR-A1307 did not result in tumor regression, however, demonstrated a trend towards inhibition of tumor growth in Tarceva (erlotinib)-resistant patient-derived xenograft (PDX) models of EGFR-positive and KRAS G12C non-small cell lung cancer (PMID: 30962319).",
            "molecularProfile": {
                "id": 32968,
                "profileName": "EGFR pos KRAS G12C"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment inhibited Erk and S6 phosphorylation, resulted in apoptosis in lung carcinoma cells harboring KRAS G12C and NRAS Q61H in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 33499,
                "profileName": "KRAS G12C NRAS Q61H"
            },
            "therapy": {
                "id": 8786,
                "therapyName": "Everolimus + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment induced apoptosis in lung carcinoma cells harboring KRAS G12C and NRAS Q61H in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 33499,
                "profileName": "KRAS G12C NRAS Q61H"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS1620, Afinitor (everolimus), and Linsitinib (OSI-906) triple combination treatment inhibited Erk and S6 phosphorylation but had no effect on apoptosis in lung carcinoma cells harboring KRAS G12C and NRAS Q61H in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 33499,
                "profileName": "KRAS G12C NRAS Q61H"
            },
            "therapy": {
                "id": 8792,
                "therapyName": "ARS1620 + Everolimus + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18688,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS1620 treatment resulted in minor reduction of Erk phosphorylation and had no effect on apoptosis in lung carcinoma cells harboring KRAS G12C and NRAS Q61H in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 33499,
                "profileName": "KRAS G12C NRAS Q61H"
            },
            "therapy": {
                "id": 7862,
                "therapyName": "ARS1620",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19326,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, MRTX849 treatment resulted in a partial response after 3 cycles of treatment in a patient with metastatic lung adenocarcinoma harboring KRAS G12C, KEAP1 K97M, and STK11 E223* (PMID: 31658955).",
            "molecularProfile": {
                "id": 34653,
                "profileName": "KEAP1 K97M KRAS G12C STK11 E223*"
            },
            "therapy": {
                "id": 7769,
                "therapyName": "MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19888,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) synergistically inhibited viability of a lung cancer cell line harboring KRAS G12C and STK11 P281fs in culture, and induced tumor regression in a cell line xenograft model (PMID: 31658955).",
            "molecularProfile": {
                "id": 34655,
                "profileName": "KRAS G12C STK11 P281fs"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19913,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and STK11 P281fs in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34655,
                "profileName": "KRAS G12C STK11 P281fs"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19334,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) synergistically inhibited viability of a lung cancer cell line harboring KRAS G12C and STK11 E317* in culture, and induced tumor regression in a cell line xenograft model (PMID: 31658955).",
            "molecularProfile": {
                "id": 34658,
                "profileName": "KRAS G12C STK11 E317*"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19911,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and STK11 E317* in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34658,
                "profileName": "KRAS G12C STK11 E317*"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19909,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and STK11 E317* in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34658,
                "profileName": "KRAS G12C STK11 E317*"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19335,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Ibrance (palbociclib) combination treatment resulted in enhanced inhibition of Rb1 phosphorylation and cell cycle progression in lung cancer cell lines harboring KRAS G12C and CDKN2A deletion, led to synergistic inhibition of cell growth in culture, and induced tumor regression in cell line and patient-derived xenograft (PDX) models (PMID: 31658955).",
            "molecularProfile": {
                "id": 34659,
                "profileName": "CDKN2A del KRAS G12C"
            },
            "therapy": {
                "id": 9001,
                "therapyName": "MRTX849 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Ibrance (palbociclib) combination treatment synergistically inhibited growth of lung cancer cell lines harboring KRAS G12C and CDK4 amplification in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34662,
                "profileName": "CDK4 amp KRAS G12C"
            },
            "therapy": {
                "id": 9001,
                "therapyName": "MRTX849 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Vistusertib (AZD2014) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 8999,
                "therapyName": "MRTX849 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20869,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing MET exon 14 skipping and KRAS G12C demonstrated decreased sensitivity to treatment with Xalkori (crizotinib) in culture compared to cells only expressing MET exon 14 skipping (PMID: 30352902).",
            "molecularProfile": {
                "id": 35373,
                "profileName": "KRAS G12C MET del exon14"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18112,
                    "pubMedId": 30352902,
                    "title": "Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30352902"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing MET exon 14 skipping and KRAS G12C demonstrated decreased sensitivity to treatment with Cometriq (Cabometyx, cabozantinib)  in culture compared to cells only expressing MET exon 14 skipping (PMID: 30352902).",
            "molecularProfile": {
                "id": 35373,
                "profileName": "KRAS G12C MET del exon14"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18112,
                    "pubMedId": 30352902,
                    "title": "Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30352902"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1042,
            "profileName": "KRAS G12C",
            "profileTreatmentApproaches": [
                {
                    "id": 15779,
                    "name": "AZD4785",
                    "profileName": "KRAS G12C"
                },
                {
                    "id": 15780,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "KRAS G12C"
                },
                {
                    "id": 15782,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "KRAS G12C"
                },
                {
                    "id": 15781,
                    "name": "MEK2 Inhibitor",
                    "profileName": "KRAS G12C"
                },
                {
                    "id": 15783,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "KRAS G12C"
                },
                {
                    "id": 15778,
                    "name": "MEK1 Inhibitor",
                    "profileName": "KRAS G12C"
                },
                {
                    "id": 15784,
                    "name": "PIK3CA inhibitor",
                    "profileName": "KRAS G12C"
                }
            ]
        },
        {
            "id": 18272,
            "profileName": "KRAS G12C YAP1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18651,
            "profileName": "FGFR4 P712T KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25299,
            "profileName": "KRAS G12C MAPK1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25300,
            "profileName": "KRAS G12C RAF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25302,
            "profileName": "BRAF dec exp KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26088,
            "profileName": "BRAF wild-type KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26341,
            "profileName": "EZH2 pos KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26366,
            "profileName": "KRAS G12C PIK3CA H1047R TP53 R248W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28338,
            "profileName": "KEAP1 loss KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28346,
            "profileName": "KRAS G12C NFE2L2 G31R NFE2L2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30253,
            "profileName": "EML4 - ALK KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30712,
            "profileName": "KRAS G12C PTPN11 P491Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32968,
            "profileName": "EGFR pos KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33499,
            "profileName": "KRAS G12C NRAS Q61H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34653,
            "profileName": "KEAP1 K97M KRAS G12C STK11 E223*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34655,
            "profileName": "KRAS G12C STK11 P281fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34658,
            "profileName": "KRAS G12C STK11 E317*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34659,
            "profileName": "CDKN2A del KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34662,
            "profileName": "CDK4 amp KRAS G12C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34670,
            "profileName": "KRAS G12C PIK3CA T1025A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35373,
            "profileName": "KRAS G12C MET del exon14",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 157052,
            "transcript": "XM_011520653",
            "gDna": "chr12:g.25245351C>A",
            "cDna": "c.34G>T",
            "protein": "p.G12C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157053,
            "transcript": "XM_006719069",
            "gDna": "chr12:g.25245351C>A",
            "cDna": "c.34G>T",
            "protein": "p.G12C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157051,
            "transcript": "XM_017019293",
            "gDna": "chr12:g.25245351C>A",
            "cDna": "c.34G>T",
            "protein": "p.G12C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157050,
            "transcript": "NM_033360",
            "gDna": "chr12:g.25245351C>A",
            "cDna": "c.34G>T",
            "protein": "p.G12C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 157049,
            "transcript": "NM_004985",
            "gDna": "chr12:g.25245351C>A",
            "cDna": "c.34G>T",
            "protein": "p.G12C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}